Aguiar Filipa, Fernandes Gabriela, Queiroga Henrique, Machado José Carlos, Cirnes Luís, Souto Moura Conceição, Hespanhol Venceslau
Pneumology Department, Hospital de Braga, Portugal.
Pneumology Department, Centro Hospitalar de São João, Portugal; Faculdade de Medicina da Universidade do Porto, Portugal.
Arch Bronconeumol (Engl Ed). 2018 Jan;54(1):10-17. doi: 10.1016/j.arbres.2017.07.012. Epub 2017 Oct 25.
Patients with activating somatic mutations in the Epidermal Growth Factor Receptor (EGFR) have better clinical outcomes when treated with Tyrosine Kinase Inhibitors (TKI) over chemotherapy. However, the impact of the use of TKIs on overall survival outside clinical trials is not well established.
To characterize and analyze the overall survival of a Caucasian population with NSCLC and EGFR mutations.
A retrospective cohort analysis of patients with NSCLC screened for EGFR mutations (exons 18-21) between October 2009 and July 2013 was conducted. Clinical and pathological characteristics, mutational EGFR status, treatment and overall survival were evaluated.
From the 285 patients which performed screening for EGFR mutations, 54 (18.9%) had mutations, 25 (46.3%) of which in exon 19 and 20 of which (37.0%) in exon 21. The occurrence of mutations was associated with female sex and non-smoking habits (both, P<.001). The median survival of the global population was 12.0 months, with a better overall survival in mutated than non-mutated patients (20.0 vs 11.0 months, respectively; P=.007).
These data contribute for a better knowledge of our lung cancer population concerning the mutational status and clinical outcomes, confirming a better overall survival for the patients with EGFR TKI sensible mutations.
与化疗相比，表皮生长因子受体（EGFR）发生激活体细胞突变的患者接受酪氨酸激酶抑制剂（TKI）治疗时临床结局更好。然而，在临床试验之外使用TKI对总生存期的影响尚未明确。
描述并分析患有非小细胞肺癌（NSCLC）且有EGFR突变的白种人群的总生存期。
对2009年10月至2013年7月期间接受EGFR突变（外显子18 - 21）筛查的NSCLC患者进行回顾性队列分析。评估临床和病理特征、EGFR突变状态、治疗情况及总生存期。
在285例接受EGFR突变筛查的患者中，54例（18.9%）有突变，其中25例（46.3%）在外显子19，20例（37.0%）在外显子21。突变的发生与女性性别和非吸烟习惯相关（均P <.001）。总体人群的中位生存期为12.0个月，突变患者的总生存期优于未突变患者（分别为20.0个月和11.0个月；P = 0.007）。
这些数据有助于更好地了解我们肺癌人群的突变状态和临床结局，证实EGFR TKI敏感突变患者的总生存期更好。
